GT201300038A - Procedimiento para preparar formas enantiomericas de derivados de acido 2,3-diaminopropionico - Google Patents

Procedimiento para preparar formas enantiomericas de derivados de acido 2,3-diaminopropionico

Info

Publication number
GT201300038A
GT201300038A GT201300038A GT201300038A GT201300038A GT 201300038 A GT201300038 A GT 201300038A GT 201300038 A GT201300038 A GT 201300038A GT 201300038 A GT201300038 A GT 201300038A GT 201300038 A GT201300038 A GT 201300038A
Authority
GT
Guatemala
Prior art keywords
procedure
diaminopropionic
enantiomeric forms
acid derivatives
prepare
Prior art date
Application number
GT201300038A
Other languages
English (en)
Inventor
1 Graf Claus-Dieter
Riekezapp Joerg
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43598042&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT201300038(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of GT201300038A publication Critical patent/GT201300038A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

LA INVENCIÓN SE REFIERE A UN PROCEDIMIENTO PARA PREPARAR LAS FORMAS ENANTIOMÉRICAS DE DERIVADOS DE ÁCIDO 2,3-DIAMINOPROPIÓNICO, POR RESOLUCIÓN DE RACEMATO. LA SEPARACIÓN DEL RACEMATO EN SUS ENANTIÓMEROS TIENE LUGAR A TRAVÉS DE LA FORMACIÓN DE SALES DIASTEREÓMERAS AL AÑADIR UN AUXILIAR ENANTIOMÉRICAMENTE PURO, Y LA SEPARACIÓN SUBSIGUIENTE MEDIANTE CRISTALIZACIÓN FRACCIONADA.
GT201300038A 2010-08-12 2013-02-11 Procedimiento para preparar formas enantiomericas de derivados de acido 2,3-diaminopropionico GT201300038A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10305884 2010-08-12
US201061428336P 2010-12-30 2010-12-30

Publications (1)

Publication Number Publication Date
GT201300038A true GT201300038A (es) 2015-06-24

Family

ID=43598042

Family Applications (1)

Application Number Title Priority Date Filing Date
GT201300038A GT201300038A (es) 2010-08-12 2013-02-11 Procedimiento para preparar formas enantiomericas de derivados de acido 2,3-diaminopropionico

Country Status (23)

Country Link
US (2) US8877926B2 (es)
EP (1) EP2603491B1 (es)
JP (1) JP6000248B2 (es)
KR (1) KR20130099044A (es)
CN (1) CN103209961A (es)
AR (1) AR082621A1 (es)
AU (1) AU2011288533A1 (es)
BR (1) BR112013002985A2 (es)
CA (1) CA2807979A1 (es)
CL (1) CL2013000420A1 (es)
CO (1) CO6690757A2 (es)
CR (1) CR20130059A (es)
DO (1) DOP2013000035A (es)
EC (1) ECSP13012434A (es)
GT (1) GT201300038A (es)
MA (1) MA34464B1 (es)
MX (1) MX2013001647A (es)
PE (1) PE20131326A1 (es)
RU (1) RU2013110525A (es)
SG (1) SG187791A1 (es)
TW (1) TW201221504A (es)
UY (1) UY33552A (es)
WO (1) WO2012019967A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201402461RA (en) 2011-12-06 2014-08-28 Sanofi Sa Crystalline forms of 2-(2-methylamino-pyrimidin-4-yl)-1h-indole-5-carboxylic acid [(s)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino)-ethyl]-amide

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19850301A1 (de) * 1998-10-30 2000-05-04 Basf Ag Verfahren zur Racematspaltung von 2-Hydroxypropionsäuren
DE19951360A1 (de) 1999-10-26 2001-05-03 Aventis Pharma Gmbh Substituierte Indole
US7462638B2 (en) 2002-08-17 2008-12-09 Sanofi-Aventis Deutschland Gmbh Use of IκB-kinase inhibitors in pain therapy
DE10237722A1 (de) 2002-08-17 2004-08-19 Aventis Pharma Deutschland Gmbh Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase
DE102004033406A1 (de) * 2004-07-10 2006-02-16 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung der enantiomeren Formen von 2,3-Diaminopropionsäurederivaten
US20070142417A1 (en) 2005-05-11 2007-06-21 Aventis Pharmaceuticals Inc Substantially Pure 2-{[2-(2-Methylamino-Pyrimidin-4-YL)-1H-Indole-5-Carbonyl]-Amino}-3-Phenylpyridin-2-YL-Amino)-Propionic Acid as an IkB Kinase Inhibitor
DE102005025225A1 (de) 2005-06-01 2006-12-07 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung von 2-(2-Amino-pyrimidin-4-yl)-1H-indol-5-carbonsäure-derivaten

Also Published As

Publication number Publication date
WO2012019967A1 (en) 2012-02-16
US20150018554A1 (en) 2015-01-15
US8877926B2 (en) 2014-11-04
SG187791A1 (en) 2013-03-28
CA2807979A1 (en) 2012-02-16
RU2013110525A (ru) 2014-09-20
JP2013533296A (ja) 2013-08-22
US9434696B2 (en) 2016-09-06
DOP2013000035A (es) 2013-03-15
CN103209961A (zh) 2013-07-17
EP2603491B1 (en) 2014-09-24
CR20130059A (es) 2013-03-25
AU2011288533A1 (en) 2013-02-28
AR082621A1 (es) 2012-12-19
US20130211085A1 (en) 2013-08-15
PE20131326A1 (es) 2013-11-12
TW201221504A (en) 2012-06-01
JP6000248B2 (ja) 2016-09-28
UY33552A (es) 2012-03-30
MX2013001647A (es) 2013-03-21
ECSP13012434A (es) 2013-03-28
BR112013002985A2 (pt) 2017-11-07
CL2013000420A1 (es) 2013-04-05
MA34464B1 (fr) 2013-08-01
KR20130099044A (ko) 2013-09-05
CO6690757A2 (es) 2013-06-17
EP2603491A1 (en) 2013-06-19

Similar Documents

Publication Publication Date Title
CL2017002854A1 (es) Sal de (s)-csa de s-ketamina, sal de (r)-csa de s-ketamina y procesos para la preparación de s-ketamin
CL2017000824A1 (es) Moduladores de regulador de conducta de transmembranas de fibrosis cística
DK2970283T3 (da) Substituerede 2-aza-bicyclo[2.2.1]heptan-3-carboxylsyre-(benzyl-cyano-methyl)-amider som inhibitorer af cathepsin-c
WO2015110897A3 (en) Novel process for the preparation of dolutegravir and pharmaceutically acceptable salts thereof
CO2017002253A2 (es) Compuesto dirigido a il-23a y tnf-alfa
CL2017002427A1 (es) Producción de ácido ribonucleico libre de células.
AR101434A1 (es) Método para producir (r)-1,1,3-trimetil-4-aminoindano
EA201691006A1 (ru) Морфологические формы гексадецилоксипропиловых сложных эфиров фосфоновой кислоты и способы их синтеза
IT201700068744A1 (it) Processo per la produzione di acido levulinico.
BR112015023218A2 (pt) formas sólidas de 5- (halometil)furfural e métodos para preparar as mesmas
BR112017018993A2 (pt) Processo para preparar 3-cloro-2- vinilfenilassulfonatos
FR3001965B1 (fr) Procede de synthese d'aminoacide par metathese, hydrolyse puis hydrogenation
CO6430457A2 (es) Proceso para la preparación de amidas del ácido pirazol carboxilico
WO2014127418A8 (en) Conjugate compound and uses of same
EP3366641A4 (en) METHOD FOR PRODUCING A CLEANED AQUEOUS SOLUTION OF SILICA
EA201791329A1 (ru) Новые кристаллические формы мононатриевой соли форамсульфурона
GT201300038A (es) Procedimiento para preparar formas enantiomericas de derivados de acido 2,3-diaminopropionico
MA39877A (fr) Formes solides d'un composé pharmaceutiquement actif
BR112015027977A2 (pt) método para a produção de formulações de óleo, formulações de óleo, e uso das formulações de óleo
CO2017010018A2 (es) Derivados de ácido (s)-2’-vinil-abscísico
BR112014012595A2 (pt) processo de racemização de ácido (s)-3-carbamoilmetil-5-metil-hexanoico
BR112014014432A2 (pt) método para produzir um composto
BR112017010403A2 (pt) método para a produção de praziquantel
FI20156006A (fi) Selektiivinen menetelmä levuliinihapon konversioon gammavalerolaktoniksi
BR112015028751A2 (pt) processo para a preparação de derivados de 3,5-bis (fluoralquil)pirazol a partir de alfa,alfa-dihaloaminas